User profiles for S. Lauer
Stephen A LauerCertilytics, Inc Verified email at certilytics.com Cited by 11616 |
Variation in false-negative rate of reverse transcriptase polymerase chain reaction–based SARS-CoV-2 tests by time since exposure
… This is why, as the commenter’s state, we made all code and data publicly available so that
the analysis can be updated as more studies are published. We have re-run the analysis with …
the analysis can be updated as more studies are published. We have re-run the analysis with …
Fipronil: environmental fate, ecotoxicology, and human health concerns
CCD Tingle, JA Rother, CF Dewhurst, S Lauer… - … Continuation of Residue …, 2003 - Springer
Fipronil is a commercial insecticide discovered and developed by Rhône-Poulenc between
1985 and 1987 and released to the market in 1993. It is a member of a relatively new and …
1985 and 1987 and released to the market in 1993. It is a member of a relatively new and …
The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application
Background: A novel human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
was identified in China in December 2019. There is limited support for many …
was identified in China in December 2019. There is limited support for many …
[HTML][HTML] Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study
Background Assessing the burden of COVID-19 on the basis of medically attended case
numbers is suboptimal given its reliance on testing strategy, changing case definitions, and …
numbers is suboptimal given its reliance on testing strategy, changing case definitions, and …
Formulations of fentanyl for the management of pain
S Grape, SA Schug, S Lauer, BS Schug - Drugs, 2010 - Springer
Fentanyl is an opioid initially developed for parenteral administration. While oral administration
is not an option due to a high first-pass metabolism, its high potency and lipophilicity …
is not an option due to a high first-pass metabolism, its high potency and lipophilicity …
Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients
…, C Atyeo, AJ Iafrate, SB Calderwood, SA Lauer… - Science …, 2020 - science.org
We measured plasma and/or serum antibody responses to the receptor-binding domain (RBD)
of the spike (S) protein of SARS-CoV-2 in 343 North American patients infected with …
of the spike (S) protein of SARS-CoV-2 in 343 North American patients infected with …
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
…, I Smith, L Gianni, J Baselga, N Al-Sakaff, S Lauer… - The Lancet, 2017 - thelancet.com
Background Clinical trials have shown that trastuzumab, a recombinant monoclonal antibody
against HER2 receptor, significantly improves overall survival and disease-free survival in …
against HER2 receptor, significantly improves overall survival and disease-free survival in …
Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study
…, M Schlatter, M Davis, R Giller, S Lauer… - Journal of pediatric …, 2004 - Elsevier
PURPOSE: The aim of this study was to perform an evaluation of outcome and the role of
surgical staging components in malignant germ cell tumors (GCT) of the ovary in children and …
surgical staging components in malignant germ cell tumors (GCT) of the ovary in children and …
Serology-informed estimates of SARS-CoV-2 infection fatality risk in Geneva, Switzerland
J Perez-Saez, SA Lauer, L Kaiser, S Regard… - The Lancet Infectious …, 2021 - thelancet.com
The infection fatality risk (IFR) is the average number of deaths per infection by a pathogen
and is key to characterising the severity of infection across the population and for specific …
and is key to characterising the severity of infection across the population and for specific …
[PDF][PDF] Complete surgical excision is effective treatment for children with immature teratomas with or without malignant elements: A Pediatric Oncology Group …
…, B Cushing, R Giller, L Cohen, SJ Lauer… - Journal of clinical …, 1999 - researchgate.net
… Patients and Methods: Patients with immature teratomas treated at Pediatric Oncology Group
or Children’s Cancer Group institutions were eligible. Pathology was centrally reviewed to …
or Children’s Cancer Group institutions were eligible. Pathology was centrally reviewed to …